Christine Pratt, PA
Allergy & Immunology · Peoria, AZNPI 1033201074
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 368 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations.
Across 368 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$658
- Sanofi$653
- AstraZeneca$606
- Genentech USA, Inc.$505
- Takeda Pharmaceuticals U.S.A., Inc.$411
- plus $3K from 29 others
What the payments were for
- Consulting fees$1442%
- Food & beverage$7,06395%
- Education$2113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 84 | $1,389 |
| Regeneron Healthcare Solutions, Inc. | 25 | $658 |
| Sanofi | 35 | $653 |
| AstraZeneca | 21 | $606 |
| Genentech USA, Inc. | 25 | $505 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $411 |
| Pfizer | 15 | $282 |
| CSL Behring | 11 | $282 |
| Novartis | 16 | $276 |
| Kaleo, Inc. | 10 | $258 |
| Grifols USA, LLC | 10 | $241 |
| Optinose US, Inc. | 11 | $226 |
| Blueprint Medicines Corporation | 8 | $197 |
| Amgen | 9 | $171 |
| ADMA Biomanufacturing LLC | 12 | $165 |
| Biocryst US Sales Co., LLC | 7 | $156 |
| Incyte Corporation | 7 | $143 |
| Octapharma USA, Inc. | 3 | $102 |
| Sanofi-aventis U.S. LLC | 2 | $101 |
| AbbVie | 6 | $87 |
| Pharming Healthcare, Inc. | 3 | $66 |
| Lilly USA, LLC | 3 | $64 |
| Kedrion Biopharma, Inc. | 3 | $56 |
| GC Biopharma USA, Inc. | 3 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Hikma Pharmaceuticals USA | 2 | $36 |
| Covis Pharma GmbH | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Organon | 3 | $23 |
| Merck | 1 | $23 |
| Bio Products Laboratory USA, Inc. | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $19 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $17 |
| LEO Pharma Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
How this compares
$7,418 in reported general payments places this provider in the 65th percentile of 90 allergy & immunology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $53,452 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $22,838 |
| Spiriva RespimatTiotropium Bromide | 19 | $12,628 |
| Azelastine Hcl | 165 | $7,071 |
| Arnuity ElliptaFluticasone Furoate | 23 | $6,927 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $5,777 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,586 |
| Epinephrine | 18 | $3,728 |
| Cromolyn Sodium | 18 | $3,673 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $3,036 |
| Pulmicort FlexhalerBudesonide | 11 | $2,967 |
| Ipratropium Bromide | 74 | $2,901 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $2,576 |
| Mometasone Furoate | 15 | $1,643 |
| Montelukast Sodium | 148 | $1,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,389 | $83,217119 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $606 | $8,55329 claims |
| Hikma Pharmaceuticals USAEpinephrine | $36 | $3,72818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 90 allergy & immunology providers in Arizona.
Other allergy & immunology in Peoria
- Gilbert OrtegaPeoria$30K
- Ronald MittelPeoria$23K
- Mark RosePeoria$21K
- Ryan CasperPeoria$20K
- Ronald JorgensenPeoria$19K
- Kevin BoeselPeoria$15K
- Eiza ChingPeoria$12K
- Gregory CowanPeoria$5K
- Levente ErdosPeoria$2K
- Michael ManningScottsdale$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.